CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (53,585)	$ (59,412)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	525	307
Amortization (accretion) on marketable securities	(182)	0
Non-cash interest expense	87	58
Non-cash lease expense	401	463
Stock-based compensation expense	7,495	7,873
Impairment of advance for COVAXIN supply	4,074	0
Loss on disposal of fixed assets related to COVAXIN	363	0
Other	379	(673)
Changes in assets and liabilities:
Prepaid expenses and other current assets	132	1,888
Accounts payable and accrued expenses	(10,059)	6,592
Lease obligations	(382)	(261)
Net cash used in operating activities	(50,752)	(43,165)
Cash flows from investing activities
Purchases of marketable securities	(3,947)	0
Proceeds from the maturities of marketable securities	17,500	0
Purchases of property and equipment	(7,754)	(2,433)
Repayment of note receivable	0	761
Net cash provided by (used in) investing activities	5,799	(1,672)
Cash flows from financing activities
Proceeds from issuance of common stock, net	20,788	51,141
Payment of equity issuance costs	(355)	(298)
Proceeds from issuance of debt	500	500
Payment of debt issuance costs	(68)	(43)
Net cash provided by financing activities	20,865	51,300
Effect of changes in exchange rate on cash and cash equivalents	2	30
Net (decrease) increase in cash and cash equivalents	(24,086)	6,493
Cash, cash equivalents, and restricted cash at beginning of period	77,563	95,109
Cash and cash equivalents at end of period	53,477	101,602
Supplemental disclosure of non-cash investing and financing transactions:
Equity issuance costs	0	2
Purchases of property and equipment	1,969	1,231
Right-of-use asset related to operating leases	0	2,916
Debt issuance costs	$ 0	$ 19